Prof Peter Hotez MD PhD+ Your Authors @PeterHotez Vaccine Scientist-Pediatrician-Author, Prof Dean @BCM_TropMed @TexasChildrens, Univ Prof @Baylor, Hagler Inst Advanced Study @TAMU, Founding Editor @PLOSNTDs Jun. 13, 2020 1 min read + Your Authors

I’m quite optimistic about this approach, both as Rx and short term pre-exposure or post-exposure prophylaxis. More thoughtful in its design than some of the vaccine candidates  https://www.cnn.com/2020/06/11/health/regeneron-covid-19-antibody-trial-starts/index.html 

Might help us navigate and manage the next couple of years until we have truly effective and safe vaccines

Hopefully we’ll keep the costs down, lots of potential for abuse given past price gouging of mabs

With our anticipated surge in Houston and Texas this would be useful to for testing here and our @TXMedCenter

Amazing to see how far this approach has progressed since I first advocated for plasma convalescent RX way back in February on my second or 3rd appearance on @NewDay, just a few weeks before the apocalypse

Like convalescent plasma, this has to be given early in the course of the illness. It means we’ll have to reconfigure the conversation or health system to provide easy access to the population, e.g. a pharmacist would give this in conjunction with a positive test or exposure


You can follow @PeterHotez.



Bookmark

____
Tip: mention @threader_app on a Twitter thread with the keyword “compile” to get a link to it.

Enjoy Threader? Sign up.

Since you’re here...

... we’re asking visitors like you to make a contribution to support this independent project. In these uncertain times, access to information is vital. Threader gets 1,000,000+ visits a month and our iOS Twitter client was featured as an App of the Day by Apple. Your financial support will help two developers to keep working on this app. Everyone’s contribution, big or small, is so valuable. Support Threader by becoming premium or by donating on PayPal. Thank you.


Follow Threader